De Novo Kidney Transplantation
Conditions
Keywords
kidney transplant, alefacept
Brief summary
The purpose of this study is to determine whether alefacept is effective and well tolerated when used with a combination of tacrolimus, mycophenolate mofetil and steroids versus a combination therapy of placebo, tacrolimus and steroids in the prevention of kidney transplant rejection.
Interventions
DRUGAlefacept
IV and subcutaneous injection
DRUGplacebo
IV and subcutaneous injection
DRUGTacrolimus
The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
DRUGMycophenolate Mofetil
Mycophenolic mofetil was administered as 750 mg twice per day orally
DRUGSteroids
Methylprednisolone or equivalent: Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus Prednisone or equivalent: Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Subject with end stage kidney disease who is a suitable candidate for primary kidney transplantation or retransplantation * Male or female subject at least 18 years of age and younger than 65 years * Subject receiving a kidney transplant from a non-human leucocyte antigen (HLA) identical living donor or deceased HLA identical/non-HLA identical donor between 5 and 59 years of age with compatible ABO blood type (Blood group system A, B, AB and 0)
Exclusion criteria
* Subject has a panel reactivity antibody grade \> 20% in the previous 6 months and/or had had a previous graft survival shorter than 1 year due to immunological reasons * Subject received a kidney transplant from a non-heart beating donor * Subject has received a kidney transplant from a 50 - 59 year old donor with two of the following three factors: history of hypertension, cerebrovascular accident as cause of death, final pre-procurement serum creatinine \> 1.5 mg/dL (united network for organ sharing \[UNOS\] expanded criteria donor) * Cold ischemia time of the donor kidney is ≥ 30 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review | 6 months | Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: * Grade IA: significant interstitial infiltration (\>25% parenchyma affected) and foci of moderate tubulitis; * Grade IB: significant interstitial infiltration (\>25% parenchyma affected) and foci of severe tubulitis; * Grade IIA: mild to moderate intimal arteritis; * Grade IIB: severe intimal arteritis comprising \>25% of the luminal area; * Grade III: transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6 | 6 months | Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated or antibody-mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
| Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6 | 6 months | Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute mixed T-cell mediated and antibody-mediated rejections within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
| Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6 | 6 months | Acute rejection diagnosed by signs and symptoms, including biopsy-confirmed or suspected (not confirmed by biopsy - i.e. no biopsy was performed or biopsy did not confirm an acute T-cell mediated rejection). The Kaplan-Meier estimate of acute rejection diagnosed by signs and symptoms within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
| Percentage of Participants With Clinically Treated Acute Rejection at Month 6 | 6 months | Patients who received immunosuppressive medications for the treatment of suspected or biopsy-confirmed acute rejections were considered to have a clinically-treated acute rejection. The Kaplan-Meier estimate of clinically treated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit. |
| Percentage of Participants With Steroid-resistant Acute Rejection at Month 6 | 6 months | A steroid-resistant acute rejection is defined as a rejection episode which did not resolve following treatment with corticosteroids. In the case that a rejection episode was not treated with corticosteroids first but only with antibodies, it was included in this category. The Kaplan-Meier estimate of steroid-resistant acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
| Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6 | 6 months | Biopsies were graded by the central reviewer according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
| Patient Survival | 6 months | Patient survival is any participant known to be alive at Month 6. The Kaplan-Meier estimate of patient survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment. |
| Graft Survival | 6 months | Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at end of study or at discontinuation of the participant unless superseded by follow-up information. The Kaplan-Meier estimate of graft survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment. |
| Maximum Histological Grade of All Biopsies After Local Review | 6 months | The grade of acute rejection was classified according to Banff 97/05 updated version. If a patient had more than 1 rejection episode, the episode with the most severe grade was used. Acute T-cell mediated rejection: * Grade IA: significant interstitial infiltration (\>25% parenchyma affected) and foci of moderate tubulitis; * Grade IB: significant interstitial infiltration (\>25% parenchyma affected) and foci of severe tubulitis; * Grade IIA: mild to moderate intimal arteritis; * Grade IIB: severe intimal arteritis comprising \>25% of the luminal area; * Grade III: transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation. Acute antibody-mediated rejection: * Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation; * Grade II: capillary-margination and/or thromboses, C4d+ * Grade III: arterial - v3, C4d+. |
| Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6 | 6 months | Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: Acute antibody-mediated rejection - documented anti-donor antibody ('suspicious for' if antibody not demonstrated): * Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation; * Grade II: capillary-margination and/or thromboses, C4d+ * Grade III: arterial - v3, C4d+. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed antibody-mediated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
| Change From Month 1 in Serum Creatinine | Month 1, 3, and 6 | — |
| Change From Month 1 in Glomerular Filtration Rate (GFR) | Month 1, 3, and 6 | The GFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula. |
| Change From Month 1 in Creatinine Clearance | Month 1, 3, and 6 | The creatinine clearance was calculated according to the Cockcroft-Gault formula. |
| GFR Measured by Iothalamate Clearance at Month 6 | Month 6 | GFR measured using the iothalamate clearance method and determined by a central laboratory. |
| Percentage of Participants With Efficacy Failure at Month 6 | 6 months | Efficacy failure is defined as death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading or lost to follow-up. The Kaplan-Meier estimate of efficacy failure within the first 6 months following transplantation is reported. |
| Percentage of Participants With Delayed Graft Function | 1 week | Delayed graft function was defined as the requirement for dialysis within the first week post-transplant. |
| Percentage of Participants With Treatment Failure at Month 6 | 6 months | Treatment failure is defined as efficacy failure (death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading, lost to follow-up) or early discontinuation of alefacept/placebo at any time (during the 12-week administration period) for any reason. The Kaplan-Meier estimate of treatment failure within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit. |
| Number of Participants With Adverse Events | 6 Months | Causally related was defined as adverse events (AEs) assessed by the Investigator as possibly or probably related to study drug or records where the relationship was missing. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: * Resulted in death. * Was life-threatening. * Resulted in persistent or significant disability/incapacity. * Resulted in congenital anomaly or birth defect. * Required patient hospitalization or led to prolongation of hospitalization * Was considered a medically important event. All rejections and any BK virus, Epstein Barr virus and/or cytomegalovirus infection had to be reported as an SAE |
| Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6 | 6 months | The Kaplan-Meier estimate of anti-lymphocyte antibody therapy for acute rejection (clinically-treated or biopsy-confirmed) within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit. |
Countries
Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Participant flow
Recruitment details
Of 221 patients screened, 218 patients were enrolled into the study at 30 centers across 12 countries.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment. | 107 |
| Alefacept Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment. | 105 |
| Total | 212 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 2 | 1 |
| Overall Study | Lost to Follow-up | 1 | 0 |
| Overall Study | Miscellaneous Reasons | 8 | 10 |
| Overall Study | Randomized but Never Received Study Drug | 3 | 3 |
| Overall Study | Withdrawal by Subject | 4 | 6 |
Baseline characteristics
| Characteristic | Placebo | Alefacept | Total |
|---|---|---|---|
| Age, Continuous | 46.5 years STANDARD_DEVIATION 11.3 | 44.2 years STANDARD_DEVIATION 11.9 | 45.4 years STANDARD_DEVIATION 11.7 |
| Sex: Female, Male Female | 33 Participants | 40 Participants | 73 Participants |
| Sex: Female, Male Male | 74 Participants | 65 Participants | 139 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 98 / 107 | 92 / 105 |
| serious Total, serious adverse events | 62 / 107 | 57 / 105 |
Outcome results
Primary
Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: * Grade IA: significant interstitial infiltration (\>25% parenchyma affected) and foci of moderate tubulitis; * Grade IB: significant interstitial infiltration (\>25% parenchyma affected) and foci of severe tubulitis; * Grade IIA: mild to moderate intimal arteritis; * Grade IIB: severe intimal arteritis comprising \>25% of the luminal area; * Grade III: transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set (all randomized and transplanted participants who received at least 1 dose of study drug)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review | 6.7 percentage of participants |
| Alefacept | Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review | 10.6 percentage of participants |
90% CI: [-2.5, 10.3]
Secondary
Change From Month 1 in Creatinine Clearance
The creatinine clearance was calculated according to the Cockcroft-Gault formula.
Time frame: Month 1, 3, and 6
Population: Full analysis set participants with available data at Month 1 (90, 84) and at Month 3 and Month 6 (indicated by n).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Month 1 in Creatinine Clearance | Change From Month 1 to Month 3 (n=81, 79) | 3.0336 mL/minute | Standard Deviation 13.97651 |
| Placebo | Change From Month 1 in Creatinine Clearance | Change From Month 1 to Month 6 (n=77, 73) | 4.5388 mL/minute | Standard Deviation 17.56456 |
| Alefacept | Change From Month 1 in Creatinine Clearance | Change From Month 1 to Month 3 (n=81, 79) | -0.5849 mL/minute | Standard Deviation 12.9516 |
| Alefacept | Change From Month 1 in Creatinine Clearance | Change From Month 1 to Month 6 (n=77, 73) | 3.0227 mL/minute | Standard Deviation 13.25005 |
Secondary
Change From Month 1 in Glomerular Filtration Rate (GFR)
The GFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Time frame: Month 1, 3, and 6
Population: Full analysis set participants with available data at Month 1 (98, 93 participants respectively) and at Month 3 and Month 6 (indicated by n).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Month 1 in Glomerular Filtration Rate (GFR) | Change From Month 1 to Month 3 (n=93, 87) | 3.1548 mL/min/1.73 m² | Standard Deviation 13.5973 |
| Placebo | Change From Month 1 in Glomerular Filtration Rate (GFR) | Change From Month 1 to Month 6 (n=83, 78) | 2.4275 mL/min/1.73 m² | Standard Deviation 15.79533 |
| Alefacept | Change From Month 1 in Glomerular Filtration Rate (GFR) | Change From Month 1 to Month 3 (n=93, 87) | 0.2889 mL/min/1.73 m² | Standard Deviation 12.54716 |
| Alefacept | Change From Month 1 in Glomerular Filtration Rate (GFR) | Change From Month 1 to Month 6 (n=83, 78) | 2.5444 mL/min/1.73 m² | Standard Deviation 13.06726 |
Secondary
Change From Month 1 in Serum Creatinine
Time frame: Month 1, 3, and 6
Population: Full analysis set participants with available data at Month 1 (99 and 94 participants in each treatment group respectively) and at Month 3 and Month 6 (indicated by n).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Month 1 in Serum Creatinine | Change From Month 1 to Month 3 (n=94, 88) | -5.0125 µmol/L | Standard Deviation 37.97017 |
| Placebo | Change From Month 1 in Serum Creatinine | Change From Month 1 to Month 6 (n=86, 81) | -6.1777 µmol/L | Standard Deviation 41.57056 |
| Alefacept | Change From Month 1 in Serum Creatinine | Change From Month 1 to Month 3 (n=94, 88) | -5.0830 µmol/L | Standard Deviation 66.25416 |
| Alefacept | Change From Month 1 in Serum Creatinine | Change From Month 1 to Month 6 (n=86, 81) | -11.7212 µmol/L | Standard Deviation 76.19852 |
Secondary
GFR Measured by Iothalamate Clearance at Month 6
GFR measured using the iothalamate clearance method and determined by a central laboratory.
Time frame: Month 6
Population: Full analysis set participants with available data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | GFR Measured by Iothalamate Clearance at Month 6 | 59.6029 mL/minute | Standard Deviation 31.36836 |
| Alefacept | GFR Measured by Iothalamate Clearance at Month 6 | 55.1613 mL/minute | Standard Deviation 26.46383 |
Secondary
Graft Survival
Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at end of study or at discontinuation of the participant unless superseded by follow-up information. The Kaplan-Meier estimate of graft survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Graft Survival | 90.6 percentage of participants |
| Alefacept | Graft Survival | 95.2 percentage of participants |
90% CI: [-1.2, 10.4]
Secondary
Maximum Histological Grade of All Biopsies After Local Review
The grade of acute rejection was classified according to Banff 97/05 updated version. If a patient had more than 1 rejection episode, the episode with the most severe grade was used. Acute T-cell mediated rejection: * Grade IA: significant interstitial infiltration (\>25% parenchyma affected) and foci of moderate tubulitis; * Grade IB: significant interstitial infiltration (\>25% parenchyma affected) and foci of severe tubulitis; * Grade IIA: mild to moderate intimal arteritis; * Grade IIB: severe intimal arteritis comprising \>25% of the luminal area; * Grade III: transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation. Acute antibody-mediated rejection: * Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation; * Grade II: capillary-margination and/or thromboses, C4d+ * Grade III: arterial - v3, C4d+.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IA | 2.8 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade III | 0.0 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - Grade I | 2.8 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - No Event | 97.2 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IB | 0.0 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IIA | 1.9 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - Grade II | 0.0 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - No Event | 93.5 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - Grade III | 0.0 percentage of participants |
| Placebo | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IIB | 1.9 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - Grade III | 0.0 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IB | 1.0 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IA | 1.9 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IIA | 4.8 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade IIB | 2.9 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - Grade III | 0.0 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - No Event | 96.2 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - Grade I | 1.9 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | Antibody Mediated Rejection - Grade II | 1.9 percentage of participants |
| Alefacept | Maximum Histological Grade of All Biopsies After Local Review | T-Cell Mediated Rejection - No Event | 89.5 percentage of participants |
Secondary
Number of Participants With Adverse Events
Causally related was defined as adverse events (AEs) assessed by the Investigator as possibly or probably related to study drug or records where the relationship was missing. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: * Resulted in death. * Was life-threatening. * Resulted in persistent or significant disability/incapacity. * Resulted in congenital anomaly or birth defect. * Required patient hospitalization or led to prolongation of hospitalization * Was considered a medically important event. All rejections and any BK virus, Epstein Barr virus and/or cytomegalovirus infection had to be reported as an SAE
Time frame: 6 Months
Population: Safety analysis set (all randomized participants who received at least one dose of study drug).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Adverse Events | AE causally related to steroids | 46 participants |
| Placebo | Number of Participants With Adverse Events | SAE causally related to tacrolimus | 14 participants |
| Placebo | Number of Participants With Adverse Events | AE causally related to alefacept/placebo | 36 participants |
| Placebo | Number of Participants With Adverse Events | SAE causally related to steroids | 11 participants |
| Placebo | Number of Participants With Adverse Events | Serious adverse events | 62 participants |
| Placebo | Number of Participants With Adverse Events | AE leading to discontinuation of alefacept/placebo | 7 participants |
| Placebo | Number of Participants With Adverse Events | AE causally related to tacrolimus | 49 participants |
| Placebo | Number of Participants With Adverse Events | AE leading to discontinuation of MMF | 8 participants |
| Placebo | Number of Participants With Adverse Events | SAE causally related to alefacept/placebo | 19 participants |
| Placebo | Number of Participants With Adverse Events | AE leading to discontinuation of tacrolimus | 8 participants |
| Placebo | Number of Participants With Adverse Events | AE causally related to MMF | 56 participants |
| Placebo | Number of Participants With Adverse Events | AE leading to discontinuation of steroids | 1 participants |
| Placebo | Number of Participants With Adverse Events | SAE causally related to MMF | 19 participants |
| Placebo | Number of Participants With Adverse Events | Deaths | 3 participants |
| Placebo | Number of Participants With Adverse Events | Any adverse event | 102 participants |
| Alefacept | Number of Participants With Adverse Events | Deaths | 1 participants |
| Alefacept | Number of Participants With Adverse Events | Any adverse event | 101 participants |
| Alefacept | Number of Participants With Adverse Events | AE causally related to alefacept/placebo | 41 participants |
| Alefacept | Number of Participants With Adverse Events | AE causally related to MMF | 56 participants |
| Alefacept | Number of Participants With Adverse Events | AE causally related to tacrolimus | 49 participants |
| Alefacept | Number of Participants With Adverse Events | AE causally related to steroids | 46 participants |
| Alefacept | Number of Participants With Adverse Events | Serious adverse events | 57 participants |
| Alefacept | Number of Participants With Adverse Events | SAE causally related to alefacept/placebo | 16 participants |
| Alefacept | Number of Participants With Adverse Events | SAE causally related to MMF | 21 participants |
| Alefacept | Number of Participants With Adverse Events | SAE causally related to tacrolimus | 20 participants |
| Alefacept | Number of Participants With Adverse Events | SAE causally related to steroids | 15 participants |
| Alefacept | Number of Participants With Adverse Events | AE leading to discontinuation of alefacept/placebo | 10 participants |
| Alefacept | Number of Participants With Adverse Events | AE leading to discontinuation of MMF | 6 participants |
| Alefacept | Number of Participants With Adverse Events | AE leading to discontinuation of tacrolimus | 3 participants |
| Alefacept | Number of Participants With Adverse Events | AE leading to discontinuation of steroids | 2 participants |
Secondary
Patient Survival
Patient survival is any participant known to be alive at Month 6. The Kaplan-Meier estimate of patient survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Patient Survival | 97.1 percentage of participants |
| Alefacept | Patient Survival | 99.0 percentage of participants |
90% CI: [-1.3, 5]
Secondary
Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6
Acute rejection diagnosed by signs and symptoms, including biopsy-confirmed or suspected (not confirmed by biopsy - i.e. no biopsy was performed or biopsy did not confirm an acute T-cell mediated rejection). The Kaplan-Meier estimate of acute rejection diagnosed by signs and symptoms within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6 | 27.4 percentage of participants |
| Alefacept | Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6 | 22.3 percentage of participants |
90% CI: [-14.9, 4.7]
Secondary
Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6
The Kaplan-Meier estimate of anti-lymphocyte antibody therapy for acute rejection (clinically-treated or biopsy-confirmed) within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6 | 4.7 percentage of participants |
| Alefacept | Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6 | 6.7 percentage of participants |
90% CI: [-3.3, 7.2]
Secondary
Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute mixed T-cell mediated and antibody-mediated rejections within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6 | 0.0 percentage of participants |
| Alefacept | Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6 | 1.0 percentage of participants |
90% CI: [-0.6, 2.5]
Secondary
Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated or antibody-mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6 | 9.3 percentage of participants |
| Alefacept | Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6 | 12.4 percentage of participants |
90% CI: [-4, 10.1]
Secondary
Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6
Biopsies were graded by the central reviewer according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6 | 9.6 percentage of participants |
| Alefacept | Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6 | 7.7 percentage of participants |
90% CI: [-8.2, 4.6]
Secondary
Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: Acute antibody-mediated rejection - documented anti-donor antibody ('suspicious for' if antibody not demonstrated): * Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation; * Grade II: capillary-margination and/or thromboses, C4d+ * Grade III: arterial - v3, C4d+. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed antibody-mediated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6 | 2.9 percentage of participants |
| Alefacept | Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6 | 3.8 percentage of participants |
90% CI: [-3.1, 5]
Secondary
Percentage of Participants With Clinically Treated Acute Rejection at Month 6
Patients who received immunosuppressive medications for the treatment of suspected or biopsy-confirmed acute rejections were considered to have a clinically-treated acute rejection. The Kaplan-Meier estimate of clinically treated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Clinically Treated Acute Rejection at Month 6 | 24.8 percentage of participants |
| Alefacept | Percentage of Participants With Clinically Treated Acute Rejection at Month 6 | 15.4 percentage of participants |
90% CI: [-18.5, 0]
Secondary
Percentage of Participants With Delayed Graft Function
Delayed graft function was defined as the requirement for dialysis within the first week post-transplant.
Time frame: 1 week
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Delayed Graft Function | 12.1 percentage of participants |
| Alefacept | Percentage of Participants With Delayed Graft Function | 7.6 percentage of participants |
90% CI: [-11.2, 2.2]
Secondary
Percentage of Participants With Efficacy Failure at Month 6
Efficacy failure is defined as death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading or lost to follow-up. The Kaplan-Meier estimate of efficacy failure within the first 6 months following transplantation is reported.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Efficacy Failure at Month 6 | 15.0 percentage of participants |
| Alefacept | Percentage of Participants With Efficacy Failure at Month 6 | 21.0 percentage of participants |
90% CI: [-2.7, 14.6]
Secondary
Percentage of Participants With Steroid-resistant Acute Rejection at Month 6
A steroid-resistant acute rejection is defined as a rejection episode which did not resolve following treatment with corticosteroids. In the case that a rejection episode was not treated with corticosteroids first but only with antibodies, it was included in this category. The Kaplan-Meier estimate of steroid-resistant acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Steroid-resistant Acute Rejection at Month 6 | 7.6 percentage of participants |
| Alefacept | Percentage of Participants With Steroid-resistant Acute Rejection at Month 6 | 5.7 percentage of participants |
90% CI: [-7.6, 3.8]
Secondary
Percentage of Participants With Treatment Failure at Month 6
Treatment failure is defined as efficacy failure (death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading, lost to follow-up) or early discontinuation of alefacept/placebo at any time (during the 12-week administration period) for any reason. The Kaplan-Meier estimate of treatment failure within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.
Time frame: 6 months
Population: Full analysis set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Treatment Failure at Month 6 | 20.6 percentage of participants |
| Alefacept | Percentage of Participants With Treatment Failure at Month 6 | 25.7 percentage of participants |
90% CI: [-4.4, 14.7]